An observational study in Pompe Disease, sponsored by Rambam Health Care Campus. Status unknown at 1 site in Israel. Open to participants aged 2 Days to 7 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-08-04.
Sponsored by Rambam Health Care Campus · Observational
The aim of the study is:
to develop a comprehensive biochemical assay for detection of Pompe disease (glycogen storage disease type II), to be implemented in the Newborn screening program among the Israeli population.
151 studies on the registry are indexed under Glycogen Storage Disease Type II; 30 are open to participants now.
This study's planned enrollment of 10,000 is above the median of 50 across 62 observational studies indexed under Glycogen Storage Disease Type II.
Browse Glycogen Storage Disease Type II studies →Rambam Health Care Campus is the lead sponsor of 456 studies on the registry; 33 are open to participants now.
Counted across the registry records on this site, refreshed daily.
10000 full-term newborns born in Northern Israel
Exclusion Criteria:
Dry blood spots would be taken for determination of Alpha Glucosidase activity using LC-MS-MS
Identification of the normal mean control value of Alpha glucosidase activity in Dry blood spots among Newborns in Israel
Time frame: Two years
This study is status unknown, as verified in Aug 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Glycogen Storage Disease Type II→
Rambam Health Care Campus